Business Context and Reporting Period
ImmunityBio, Inc. (IBRX) filed a Current Report on Form 8-K dated March 30, 2026. The filing details a Second Amendment to a Revenue Interest Purchase Agreement (RIPA) and a partial conversion of a convertible promissory note. The company is incorporated in Delaware and trades on The Nasdaq Global Select Market.
Key Financial Metrics and Transactions
- Capital Raised: The company received a gross purchase price of $75.0 million ("Third Payment") from purchasers under the amended RIPA.
- Debt Reduction: Nant Capital, LLC converted $25.0 million of principal debt into 4,606,596 shares of Common Stock.
- Remaining Debt: Following the conversion, the principal amount outstanding under the Convertible Promissory Note is $480.0 million.
- Revenue Interest Rates: Quarterly payments to purchasers are based on a tiered range of 5.625% to 12.50% of net sales in the Covered Territory (excluding China, Hong Kong, and controlled territories).
- Payment Cap: Revenue Interest Payments terminate once purchasers receive an aggregate amount equal to 195% of the Cumulative Purchaser Payments.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements or prior period revenue/profit data. The material changes reported are:
- Increased Revenue Interest Rates: The tiered revenue interest rate increased from a previous range of 4.5% to 10.0% to a new range of 5.625% to 12.50%.
- Adjusted Termination Rate: The single rate applicable if cumulative payments exceed $375.0 million by the end of 2029 increased from 2.25% to 2.8125%.
- Balance Sheet Impact: The company's debt load decreased by $25.0 million due to the note conversion, while equity increased by the issuance of approximately 4.6 million shares.
Guidance, Outlook, and Risks
- Use of Proceeds: The $75.0 million proceeds will be used for general corporate purposes and transaction expenses.
- Contingent Rate Adjustment: If aggregate Revenue Interest Payments do not reach $375.0 million by the end of 2029, the rate will increase to a defined single rate calculated to ensure purchasers receive the target cumulative amount.
- Collateral: The company and its subsidiary guarantors have granted a security interest in substantially all assets to secure obligations under the RIPA.
- Related Party Transaction: The note conversion involved Nant Capital, LLC, an entity affiliated with the company's Executive Chairman and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong.
Investor Verification Checklist
- Verify the exact terms of the "defined rate" calculation for the post-2029 period if the $375.0 million threshold is not met.
- Review the full text of the Second Amendment (Exhibit 10.1) for specific exceptions to the security interest granted on company assets.
- Confirm the impact of the 4,606,596 new shares on total outstanding share count and potential dilution.
- Assess the company's current net sales trajectory to determine the immediate cash flow impact of the increased 5.625% to 12.50% revenue interest rates.